Artx-413

Artx-413 is a preclinical-stage oral small molecule therapeutic being developed by Artus Therapeutics for the treatment of gastrointestinal, neurological, and metabolic disorders. It is part of a pipeline of new molecular entities inspired by beneficial naturally occurring host or microbial metabolites. The drug's primary mechanism of action involves enhancing epithelial and endothelial barrier integrity to facilitate mucosal healing. By specifically targeting gut barrier dysfunction, Artx-413 aims to address inflammatory and metabolic diseases without compromising the host's immune system, representing a first-in-class approach to treating conditions associated with compromised barrier function across multiple organ systems.